Interferon-alpha recombinant - SciVac Ltd

Drug Profile

Interferon-alpha recombinant - SciVac Ltd

Alternative Names: SciFeron

Latest Information Update: 30 Oct 2015

Price : $50

At a glance

  • Originator SciGen
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Haematological disorders; Viral infections

Most Recent Events

  • 12 Sep 2005 This programme is still in active development (BIO-2005)
  • 11 Jul 2003 Preclinical trials in Viral infections in Singapore (unspecified route)
  • 11 Jul 2003 Preclinical trials in Haematological disorders in Singapore (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top